
SPSN Report #1, 2026-27 Season
Epi-weeks 35 to 42: August 30 to October 24, 2026

The 2026/27 SPSN vaccine effectiveness (VE) monitoring period has begun. **All sentinels should have by now switched to the 2026/27 kits and should ensure to fully complete the 2026/27 SPSN questionnaires**. From epi-weeks 35-42, positivity was highest for entero/rhinoviruses (36%) and influenza (12%), otherwise remaining <10% for other pathogens. **Influenza activity has shown early increase in 2026/27, especially in BC, with influenza A(H1N1)pdm09 accounting for the majority of detections in all provinces.**

Figure 1. Tally of specimens submitted to the SPSN, epi-weeks 35-42, 2026 (N=1672)



Includes specimens from both 2025-26 and 2026-27 requisitions with test dates provided and collected within 7 days of acute respiratory illness onset. All tallies are subject to change as the season progresses and data become more complete, notably for the most recent weeks. See Table 2 for the overall tally of specimens tested by age group and province. See Figure 2 for test-positivity findings by province.
"Other" includes parainfluenza, human metapneumovirus, adenovirus, *Mycoplasma pneumoniae*, *Chlamydophila pneumoniae* and *Legionella pneumoniae*.
Among influenza viruses, 190/197 (96%) were influenza A. Of subtyped influenza A viruses, 170/176 (97%) were A(H1) and 6/176 (3%) were A(H3).
Among SPSN specimens overall, a total of 25 were diagnosed with co-infections, mostly involving influenza and another respiratory virus.

For additional respiratory virus surveillance findings specific to British Columbia (BC), see Figure 2, and consult the BC Centre for Disease Control (BCCDC) respiratory dashboard, available here.


Table 1. Strains recommended by the World Health Organization for the northern hemisphere's 2026-27 egg-based vaccine.

Season	A(H1N1)pdm09	A(H3N2)	B/Victoria[a]	B/Yamagata
2025-26 (prior)	A/Victoria/4897/2022 (clade 5a.2a.1) [subclade D][b]	A/Croatia/10136RV/2023 (clade 2a.3a.1) [subclade J.2][b]	B/Austria/1359417/2021 (clade V1A.3a.2) [subclade C][b]	B/Phuket/3073/2013 (clade Y3)
2026-27 (current)	A/Missouri/11/2025 (clade 5a.2a.1) [subclade D.3.1][b]	A/Darwin/1454/2025[c] (clade 2a.3a.1) [subclade K][b]	B/Tokyo/EIS13-175/2025[d] (clade V1A.3a.2) [subclade C.3.1][b]	-

[a] Recommended component of trivalent vaccine whereas quadrivalent vaccine includes both B/Victoria and B/Yamagata lineages
[b] Nextstrain subclade nomenclature
[c] Recommended cell-based vaccine strain (differs from egg-based strain): A/Darwin/1415/2025 (clade 2a.3a.1) [subclade K]
[d] Recommended cell-based vaccine strain (differs from egg-based strain): B/Pennsylvania/14/2025 (clade V1A.3a.2) [subclade C.3.1]


Figure 2. Weekly testing and percent positivity among SPSN specimens by province, epi-weeks 35-42, 2026

a) British Columbia




Specimens from both 2025-26 and 2026-27 requisitions are displayed. All tallies are subject to change as the season progresses and data become more complete, notably for the most recent weeks.

b) Alberta




Specimens from both 2025-26 and 2026-27 requisitions are displayed. All tallies are subject to change as the season progresses and data become more complete, notably for the most recent weeks.

c) Ontario



Specimens from both 2025-26 and 2026-27 requisitions are displayed. All tallies are subject to change as the season progresses and data become more complete, notably for the most recent weeks.

d) Quebec



Specimens from both 2025-26 and 2026-27 requisitions are displayed. All tallies are subject to change as the season progresses and data become more complete, notably for the most recent weeks.

Table 2. Specimens submitted to the SPSN by province and age group, epi-weeks 35-42, 2026 (N=1672)

Province	<5 years	5-8 years	9-19 years	20-49 years	50-64 years	65+ years	Total
Alberta	18	9	35	86	37	44	229
British Columbia	17	10	55	132	60	89	363
Ontario	58	24	79	272	132	192	757
Quebec	36	14	15	97	63	98	323
Total	129	57	184	587	292	423	1672

Table 3. Additional resources for respiratory pathogen surveillance

Canada
BCCDC - Respiratory Disease Dashboard
PHAC - FluWatch Surveillance
PHAC - Human Emerging Respiratory Pathogens Bulletins

United States
Washington State - Influenza Updates
California State - Influenza and Respiratory Disease Surveillance Report
CDC - Weekly Influenza Surveillance Report

Europe
ECDC - European Respiratory Virus Surveillance Summary

Oceania
Australian Influenza Surveillance Reports
New Zealand Institute of Environmental Science and Research (ESR) - Acute Respiratory Illness Infections Dashboard

South Africa
National Institute for Communicable Diseases - Weekly Respiratory Pathogens Surveillance Report

World Health Organization
Global Influenza Updates
Weekly Epidemiological Record
Recommendations for Influenza Vaccine Composition
Influenza at the Human-Animal Interface Summary and Assessment Updates

World Organization for Animal Health
OFFLU - Animal influenza